US4960694A - Test combination and method of detecting fibrin monomers in blood - Google Patents
Test combination and method of detecting fibrin monomers in blood Download PDFInfo
- Publication number
- US4960694A US4960694A US07/071,799 US7179987A US4960694A US 4960694 A US4960694 A US 4960694A US 7179987 A US7179987 A US 7179987A US 4960694 A US4960694 A US 4960694A
- Authority
- US
- United States
- Prior art keywords
- blood
- test
- fibrin monomers
- plasma
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 22
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 210000004369 blood Anatomy 0.000 title claims abstract description 16
- 239000008280 blood Substances 0.000 title claims abstract description 16
- 108010073385 Fibrin Proteins 0.000 title abstract description 16
- 102000009123 Fibrin Human genes 0.000 title abstract description 16
- 229950003499 fibrin Drugs 0.000 title abstract description 15
- 239000000178 monomer Substances 0.000 title abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- FSUPKDUNLKQBCN-UHFFFAOYSA-N 1H-pyrrole-2-carboximidamide Chemical class NC(=N)C1=CC=CN1 FSUPKDUNLKQBCN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000003115 biocidal effect Effects 0.000 claims abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 6
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 5
- 239000007853 buffer solution Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 claims description 14
- 108010042309 Netropsin Proteins 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 108010073651 fibrinmonomer Proteins 0.000 claims description 4
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 108010042747 stallimycin Proteins 0.000 claims description 4
- 229930191069 Anthelvencin Natural products 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 5
- 210000002381 plasma Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000012716 precipitator Substances 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- VUOPFFVAZTUEGW-SRXUPNLNSA-N 32p08cbb99 Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-SRXUPNLNSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010062729 ristocetin A Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- QZOOZUGORDEYCC-UHFFFAOYSA-N 4-[[4-[[1-amino-2-(diaminomethylideneamino)ethylidene]amino]-1-methylpyrrole-2-carbonyl]amino]-n-(3-amino-3-oxopropyl)-1-methylpyrrole-2-carboxamide;hydron;chloride Chemical compound Cl.C1=C(C(=O)NCCC(N)=O)N(C)C=C1NC(=O)C1=CC(N=C(N)CN=C(N)N)=CN1C QZOOZUGORDEYCC-UHFFFAOYSA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003027 hypercoagulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
Definitions
- the present invention relates to a test reagent for detecting fibrin monomers and a method of detecting the same in human blood plasma.
- fibrin monomers in blood is a proof of an activation of the hemostasis system. This is a clinically frequently occurring symptom of many basic illnesses. Therefore, after the hypercoagulation stage, locally caused thromboses or generally coagulation pathologies can develop with resulting heavy bleeding. The possible early detection of coagulating activity is a prerequisite for an effective therapy.
- the test suitable for the diagnosing of von Willebrand's disease based on the precipitator Ristocetin-A is used for detecting of fibrin monomers (K. WATANABE and J. L. TULLIS, Amer. J. Clin. Pathol. 70, 1978, 691; G. PFLIEGLER et al. Abstr. Int. Congr. ISH-ISBT, Budapest, Aug. 1982, p. 380).
- Numerous comparative tests have shown that with the above listed precipitators, an nonspecific precipitation with fibrin cleavage products takes place, and with increasing thrombocyte content of the plasma used for detection, falsely positive reactions are obtained so that the reliability of the test is not guaranteed.
- various further methods which are connected with expensive analysis techniques are known (affinity chromatography gel-filtration).
- test reagent which contains an antibiotic of the pyrrole-amidine series as a precipitator introduced in a buffer solution.
- pyrrole-amidine series antibiotics as netropsin, distamycin, anthelvencin or analogs introduced in HEPES-buffer are used.
- the selected pyrrole-amidine series antibiotic is used in its salt form, for example substantially as its hydrochloride.
- Still another feature of the present invention is a method of detecting fibrin monomers in human blood, in accordance with which human blood is mixed with an anticoagulant in a known manner, then centrifuged and the citrate plasma is mixed for precipitation with the above mentioned new test reagent. Then precipitation reaction, or in other words the precipitate sedimented on the bottom of the test vessel, is analyzed in a known manner.
- the plasma with the precipitant or in other words with the test reagent in accordance with the present invention is maintained under room temperature and subsequently centrifuged.
- a very cost favorable precipitant can be used such as for example netropsin hydrochloride, and high diagnostic reliability is guaranteed.
- a test reagent contains an antibiotic of the pyrrole-amidine series raw as a precipitant, introduced in a buffer solution.
- the pyrrole-amidine series antibiotic can be netropsin, distamycin, and anthelvencin or analogs
- the buffer solution can be a HEPES-buffer.
- the selected pyrrole-amidine series antibiotic can be in its salt form, for example as a hydrochloride.
- human blood is mixed in a known manner with an anticoagulant, then centrifuged, and the citrate plasma is mixed for precipitation with the above described new test reagent. Then, the precipitation reaction, or in other words the precipitate sedimented, is analyzed.
- the plasma provided with the precipitant or in other words with the test reagent of the invention is held under room temperature for the evaluation, and then centrifuged.
- Venous blood is recovered exactly in accordance with the rules applicable for coagulation tests and citrate plasma is prepared in accordance with conventional methods.
- Netropsin-HCl is dissolved in accordance with the requirements in a concentration of 15 mg netropsin/ml with HEPES-buffer (0.15 molar, pH 7.5) so that a test reagent Netropsin RL is produced.
- the probes evaluated as negative in this manner are transferred to black small block dishes and again evaluated A negative evaluation of course corresponds to fibrin monomers not being detected, while the more positive the evaluation the stronger is the indication of fibrin monomers.
- a positive control for comparison is carried for each measuring row.
- the preparation, performance and evaluation of the precipitation is carried out as in the Example I.
- the precipitant in this example is, however, distamycin-HCl, which is dissolved in a concentration of 6 mg/ml in a HEPES-buffer (test reagent Distamycin RL).
- the sensitivity of this precipitation amounts to approximately 50%, as compared with netropsin.
- a fibrinogen-dependent influence on the test result could be not found till a plasma fibrinogen concentration of 19 g/l is reached.
- the test was not influenced by changes in the albumin, alpha-globulin, immunglobulin-G and the total albumin concentration of the plasma.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A test reagent for detecting fibrin monomers in blood, comprises an antibiotic of a pyrrole amidine series as a precipitant, introduced in a buffer solution. A method of detecting fibrin monomers in blood, comprises the steps of mixing venous blood with an anticoagulant, centrifuging the mixture of the venous blood with the anticoagulant, removing a citrate plasma, using an antibiotic of a pyrrole amidine series as a precipitant, and evaluating a precipitation reaction which takes place thereby.
Description
The present invention relates to a test reagent for detecting fibrin monomers and a method of detecting the same in human blood plasma.
The appearance of fibrin monomers in blood is a proof of an activation of the hemostasis system. This is a clinically frequently occurring symptom of many basic illnesses. Therefore, after the hypercoagulation stage, locally caused thromboses or generally coagulation pathologies can develop with resulting heavy bleeding. The possible early detection of coagulating activity is a prerequisite for an effective therapy.
Several principles for detecting the fibrin monomers are known in the art. The oldest methods include the ethanol-gelatin test in accordance with GODAL (H. GODAL and U. ABILGAARD, Scand. J. Haem. 3, 1966, 342) and the protamine sulfate test in accordance with LIPPINSKI (B. LIPPINSKI and K. WAROWSKI, Thromb. Diath. Haem. 20, 1968, 44). These methods are easy to carry out. However, they show an insufficient sensitivity and specificity. A specific test is the agglutination test with fibrin monomer loaded erythrocytes in accordance with LARGO (R. LARGO et al., Blood 47, 1976, 991). Furthermore, the test suitable for the diagnosing of von Willebrand's disease based on the precipitator Ristocetin-A (Ristomycin-A) is used for detecting of fibrin monomers (K. WATANABE and J. L. TULLIS, Amer. J. Clin. Pathol. 70, 1978, 691; G. PFLIEGLER et al. Abstr. Int. Congr. ISH-ISBT, Budapest, Aug. 1982, p. 380). Numerous comparative tests have shown that with the above listed precipitators, an nonspecific precipitation with fibrin cleavage products takes place, and with increasing thrombocyte content of the plasma used for detection, falsely positive reactions are obtained so that the reliability of the test is not guaranteed. In addition to the above methods, also various further methods which are connected with expensive analysis techniques are known (affinity chromatography gel-filtration).
Accordingly, it is an object of the present invention to provide a new test reagent for detecting fibrin monomers in human blood.
It is also an object of the present invention to provide, on the basis of the proposed new test reagent, an economical method of detecting fibrin monomers by precipitation.
In keeping with these objects and with others which will become apparent hereinafter, one feature of the present invention resides, briefly stated, in a test reagent which contains an antibiotic of the pyrrole-amidine series as a precipitator introduced in a buffer solution.
In accordance with an advantageous feature of the present invention, in the new test reagent such pyrrole-amidine series antibiotics as netropsin, distamycin, anthelvencin or analogs introduced in HEPES-buffer are used.
In accordance with a further advantageous feature of the present invention the selected pyrrole-amidine series antibiotic is used in its salt form, for example substantially as its hydrochloride.
Still another feature of the present invention is a method of detecting fibrin monomers in human blood, in accordance with which human blood is mixed with an anticoagulant in a known manner, then centrifuged and the citrate plasma is mixed for precipitation with the above mentioned new test reagent. Then precipitation reaction, or in other words the precipitate sedimented on the bottom of the test vessel, is analyzed in a known manner.
In accordance with still a further feature of the inventive method, the plasma with the precipitant or in other words with the test reagent in accordance with the present invention is maintained under room temperature and subsequently centrifuged.
When the test composition is made and the method is performed in accordance with the present invention, a very cost favorable precipitant can be used such as for example netropsin hydrochloride, and high diagnostic reliability is guaranteed.
In accordance with the present invention a test reagent contains an antibiotic of the pyrrole-amidine series raw as a precipitant, introduced in a buffer solution. Advantageously, the pyrrole-amidine series antibiotic can be netropsin, distamycin, and anthelvencin or analogs, and the buffer solution can be a HEPES-buffer. The selected pyrrole-amidine series antibiotic can be in its salt form, for example as a hydrochloride.
In accordance with the method of the invention, human blood is mixed in a known manner with an anticoagulant, then centrifuged, and the citrate plasma is mixed for precipitation with the above described new test reagent. Then, the precipitation reaction, or in other words the precipitate sedimented, is analyzed. The plasma provided with the precipitant or in other words with the test reagent of the invention is held under room temperature for the evaluation, and then centrifuged.
The advantages of the inventive solution for detecting fibrin monomers is illustrated by two examples presented hereinbelow:
Venous blood is recovered exactly in accordance with the rules applicable for coagulation tests and citrate plasma is prepared in accordance with conventional methods.
Netropsin-HCl is dissolved in accordance with the requirements in a concentration of 15 mg netropsin/ml with HEPES-buffer (0.15 molar, pH 7.5) so that a test reagent Netropsin RL is produced.
0.4 ml citrate plasma is mixed with 0.1 ml netropsin-RL in a centrifuge tube and is retained for 30 minutes at room temperature. Then this tube is centrifuged for 5 minutes with maximum 50 r.p.m. The precipitate formed on the bottom is evaluated in accordance with the following diagram:
______________________________________
flaky loose precipitation
+
fibrous deposits ++
compact sediments +++
______________________________________
The probes evaluated as negative in this manner are transferred to black small block dishes and again evaluated A negative evaluation of course corresponds to fibrin monomers not being detected, while the more positive the evaluation the stronger is the indication of fibrin monomers.
A positive control for comparison is carried for each measuring row.
The preparation, performance and evaluation of the precipitation is carried out as in the Example I. The precipitant in this example is, however, distamycin-HCl, which is dissolved in a concentration of 6 mg/ml in a HEPES-buffer (test reagent Distamycin RL). The sensitivity of this precipitation amounts to approximately 50%, as compared with netropsin.
With the utilization of the inventive test reagent Netropsin RL and the respective methods, the following results were obtained in clinical laboratory tests:
Examination of the testing method for its analytical usefulness.
In vitro produced fibrin monomer containing plasma showed clearly a positive reaction.
From split products of fibrinogens and fibrins (e-FDP, 1-FDP, e-fdp, 1-fdp) recovered in individual preparation, only the fraction of the early fibrin cleavage product (e-fdp) is detected. Since e-fdp is also a product of a thrombin-caused fibrinogen conversion, the specificity of the test is not effected. From a concentration of the low molecular salt products fragment D (0.3 g/1) and fragment E (0.15 g/1) a weakening of the precipitation is observed.
A fibrinogen-dependent influence on the test result could be not found till a plasma fibrinogen concentration of 19 g/l is reached.
An influence of heparin on the precipitation could not be observed.
There was no dependency of the precipitation on thrombocyte content of the used plasma.
There was no influence of plasma expanders upon dextran- and gelatin base.
The test was not influenced by changes in the albumin, alpha-globulin, immunglobulin-G and the total albumin concentration of the plasma.
The examination of 40 hemostatically healthy hospitalized patients using conventional blood taking techniques for the coagulation test produces a negative test result in all cases (specificity=1.0).
40 patients with clinically and laboratory-diagnostically reliably disseminated intravascular coagulation were subjected to the above described test, and in 37 cases a positive result was achieved. Thereby the method can be considered with a sensitivity of 0.93 as a suitable laboratory parameter for diagnosing of the disseminated intravascular coagulation.
It will be understood that each of the elements described above, or two or more together, may also find a useful application in other types of test combinations and methods differing from the types described above.
While the invention has been illustrated and described as embodied in a test reagent and method it is not intended to be limited to the details shown, since various modifications and structural changes may be made without departing in any way from the spirit of the present invention.
Without further analysis, the foregoing will so fully reveal the gist of the present invention that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this invention.
Claims (4)
1. A method of detecting the presence of fibrin monomer in blood comprising the steps of:
a. mixing venous blood with an anticoagulant to form a mixture,
b. centrifuging said mixture,
c. removing plasma from said mixture,
d. mixing said plasma with a test reagent comprising an antibiotic of the pyrrole-amidine series dissolved in a buffer solution to from a reaction mixture, and
e. evaluating said reaction mixture for the presence of a precipitate indicative of the presence of said fibrin monomer in said blood.
2. The method of claim 1, further comprising before said step of evaluating, allowing said reaction mixture to stand for 30 minutes at room temperature and then centrifuging the same.
3. The method of claim 1, employing said antibiotic selected from the group consisting of netropsin, anthelvencin, distamycin and analogs thereof.
4. The method of claim 1, wherein said buffer is an HEPES-buffer solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD2922981 | 1986-07-09 | ||
| DD86292298A DD261844A1 (en) | 1986-07-09 | 1986-07-09 | METHOD FOR PRACTICING FIBRINMONOMERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4960694A true US4960694A (en) | 1990-10-02 |
Family
ID=5580752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/071,799 Expired - Fee Related US4960694A (en) | 1986-07-09 | 1987-07-09 | Test combination and method of detecting fibrin monomers in blood |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4960694A (en) |
| EP (1) | EP0253255A3 (en) |
| JP (1) | JPS6327762A (en) |
| DD (1) | DD261844A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441892A (en) * | 1992-10-15 | 1995-08-15 | Medtronic Hemptec, Inc. | Blood clot mass measuring technique |
| US5626757A (en) * | 1994-02-22 | 1997-05-06 | Advanced Separation Technologies Inc. | Macrocyclic antibiotics as separation agents |
| US5739288A (en) * | 1992-10-08 | 1998-04-14 | Bristol-Myers Squibb Company | Fibrin sealant compositions |
| US6436655B1 (en) | 1998-02-09 | 2002-08-20 | Medical Devices Corporation | Rapid quantitative measurement of soluble fibrin in opaque body fluids |
| US7699966B2 (en) | 2004-05-17 | 2010-04-20 | Medtronic, Inc. | Point of care heparin determination system |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3990947A (en) * | 1975-03-07 | 1976-11-09 | Warner-Lambert Company | Composition for detecting fibrinogen, fibrinogen split products and fibrin split products |
| US4145185A (en) * | 1977-02-25 | 1979-03-20 | Research Triangle Institute | Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas |
| US4210420A (en) * | 1978-11-13 | 1980-07-01 | Ortho Diagnostics Inc. | Detection of fibrin monomer and composition therefor |
| US4429040A (en) * | 1980-05-08 | 1984-01-31 | Boehringer Mannheim Gmbh | Method and reagent for the detection of fibrin monomer |
| US4692406A (en) * | 1983-08-25 | 1987-09-08 | Boehringer Mannheim Gmbh | Process and a reagent for the simultaneous determination of fibrinogen and fibrinogen fission products in plasma |
| US4710459A (en) * | 1984-08-22 | 1987-12-01 | Boehringer Mannheim Gmbh | Process and reagent for the determination of fibrin monomer in plasma |
| US4766142A (en) * | 1985-07-16 | 1988-08-23 | Farmitalia Carlo Erba S.R.L. | Poly-4-aminopyrrole-2-carboxamido derivatives and their use as antiuiral or antitumor agents |
-
1986
- 1986-07-09 DD DD86292298A patent/DD261844A1/en not_active IP Right Cessation
-
1987
- 1987-06-30 JP JP62163834A patent/JPS6327762A/en active Pending
- 1987-07-06 EP EP87109687A patent/EP0253255A3/en not_active Withdrawn
- 1987-07-09 US US07/071,799 patent/US4960694A/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3990947A (en) * | 1975-03-07 | 1976-11-09 | Warner-Lambert Company | Composition for detecting fibrinogen, fibrinogen split products and fibrin split products |
| US4145185A (en) * | 1977-02-25 | 1979-03-20 | Research Triangle Institute | Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas |
| US4210420A (en) * | 1978-11-13 | 1980-07-01 | Ortho Diagnostics Inc. | Detection of fibrin monomer and composition therefor |
| US4429040A (en) * | 1980-05-08 | 1984-01-31 | Boehringer Mannheim Gmbh | Method and reagent for the detection of fibrin monomer |
| US4692406A (en) * | 1983-08-25 | 1987-09-08 | Boehringer Mannheim Gmbh | Process and a reagent for the simultaneous determination of fibrinogen and fibrinogen fission products in plasma |
| US4710459A (en) * | 1984-08-22 | 1987-12-01 | Boehringer Mannheim Gmbh | Process and reagent for the determination of fibrin monomer in plasma |
| US4766142A (en) * | 1985-07-16 | 1988-08-23 | Farmitalia Carlo Erba S.R.L. | Poly-4-aminopyrrole-2-carboxamido derivatives and their use as antiuiral or antitumor agents |
Non-Patent Citations (3)
| Title |
|---|
| Biological Abstract 85:13421. * |
| Patel, D., "Antibiotic-DNA Interactions: Intermolecular Nuclear Overhauser Effects in the Netropsin-d(C-G-C-G-A-A-T-T-C-G-C-G) Complex in Solution", Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 6424-6428, Nov. 1982. |
| Patel, D., Antibiotic DNA Interactions: Intermolecular Nuclear Overhauser Effects in the Netropsin d(C G C G A A T T C G C G) Complex in Solution , Proc. Natl. Acad. Sci., U.S.A., vol. 79, pp. 6424 6428, Nov. 1982. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739288A (en) * | 1992-10-08 | 1998-04-14 | Bristol-Myers Squibb Company | Fibrin sealant compositions |
| US5441892A (en) * | 1992-10-15 | 1995-08-15 | Medtronic Hemptec, Inc. | Blood clot mass measuring technique |
| US5626757A (en) * | 1994-02-22 | 1997-05-06 | Advanced Separation Technologies Inc. | Macrocyclic antibiotics as separation agents |
| US5874005A (en) * | 1994-02-22 | 1999-02-23 | The Curators Of The University Of Missouri | Macrocyclic antibiotics as separation agents |
| US5964996A (en) * | 1994-02-22 | 1999-10-12 | Curators Of The University Of Missouri | Macrocyclic antibiotics as separation agents |
| US6669842B1 (en) | 1994-02-22 | 2003-12-30 | Curators Of The University Of Missouri | Macrocyclic antibiotics as separation agents |
| US6436655B1 (en) | 1998-02-09 | 2002-08-20 | Medical Devices Corporation | Rapid quantitative measurement of soluble fibrin in opaque body fluids |
| US7699966B2 (en) | 2004-05-17 | 2010-04-20 | Medtronic, Inc. | Point of care heparin determination system |
| US20100181210A1 (en) * | 2004-05-17 | 2010-07-22 | Wei Qin | Point of Care Heparin Determination System |
| US8801918B2 (en) | 2004-05-17 | 2014-08-12 | Medtronic, Inc. | Point of care heparin determination system |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0253255A3 (en) | 1990-06-13 |
| DD261844A1 (en) | 1988-11-09 |
| JPS6327762A (en) | 1988-02-05 |
| EP0253255A2 (en) | 1988-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Visentin et al. | Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. | |
| Arepally et al. | Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia | |
| Margolis | The kaolin clotting time: a rapid one-stage method for diagnosis of coagulation defects | |
| Carr et al. | Diagnosis of disseminated intravascular coagulation: role of D-dimer | |
| Aznar et al. | Activated protein C resistance phenotype in patients with antiphospholipid antibodies | |
| Kario et al. | Factor VII hyperactivity in the elderly | |
| US5552290A (en) | Detection of procoagulant platelet-derived microparticles in whole blood | |
| Rak et al. | Plasma levels of beta-thromboglobulin and factor VIII-related antigen in diabetic children and adults | |
| US4960694A (en) | Test combination and method of detecting fibrin monomers in blood | |
| Manthorpe et al. | Pseudothrombocytopenia: In vitro studies on the underlying mechanism | |
| Morse et al. | Automated fibrinogen determination | |
| Alving et al. | In vitro studies of heparin-associated thrombocytopenia | |
| US3853710A (en) | Serum diagnostic test for maladies causing change in fibrinolytic activity in the blood | |
| JPS6360862B2 (en) | ||
| Nishida et al. | A new rapid and simple assay for factor XIII activity using dansylcadaverine incorporation and gel filtration | |
| Stockman et al. | Specificity of the latex test for cryptococcal antigen: a rapid, simple method for eliminating interference factors | |
| Bénéteau‐Burnat et al. | Evaluation of stratus® CS Stat fluorimetric analyser for measurement of cardiac markers Troponin I (cTnI), creatine kinase MB (CK‐MB), and myoglobin | |
| US4245040A (en) | Detection and measurement of circulating fibrin | |
| US3960669A (en) | Urine diagnostic test for fibrinolytic activity | |
| Steinberg et al. | Platelet hypersensitivity and intravascular coagulation in paroxysmal nocturnal hemoglobinuria | |
| US4295855A (en) | Method for separating fibrinogen and its constituent components | |
| EP0398292B1 (en) | Diagnostic composition for rheumatoid arthritis | |
| DE69025008T2 (en) | Method for direct chemical binding of the D-dimer from a biological sample for the diagnosis and monitoring of thrombolytic and hypercoagulable conditions | |
| Al-Jaouni | Primary thrombophilia in Saudi Arabia | |
| Woerner et al. | Abnormal globulins in myocardial infarction: with special reference to a material coating erythrocytes and a cold-insoluble protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19941005 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |